eLife3 天
C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
This important study provides solid in-vivo evidence that CCR4 regulates the early inflammatory response during atherosclerotic plaque formation. The authors propose that altered T-cell response plays ...
Medpage Today on MSN3 天
Protein Drivers of Heart Attack Risk Disproportionately Affect Women
Sex-specific molecules contributing to one's risk of myocardial infarction (MI) were identified by researchers using ...
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist ...
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that ...